Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 1, 2006. The report details a specific corporate action regarding share repurchases authorized by shareholders at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share buyback transaction:
- Shares Purchased: 500,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,479.46 pence per share.
- Total Treasury Shares Held: 168,534,678 shares following the transaction.
- Shares in Issue: 5,813,672,154 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through the purchase of 500,000 shares for Treasury. The filing does not provide comparative data against prior periods for operational or financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Key Facts for Investor Verification
- Verify the total cost of the 500,000 share repurchase based on the disclosed price of 1,479.46 pence.
- Confirm the updated total share count and Treasury holdings as of June 1, 2006.
- Note that this filing is a notification of a specific transaction and does not include quarterly or annual financial results.